Eli Lilly and Company

Eli Lilly and Company
legal form	Corporation
ISIN	US5324571083
founding	1876
Seat	Indianapolis , Indiana , United States;
management	David A. Ricks ( CEO )
Number of employees	33,625
sales	22.3 billion US dollars
Website	www.lilly.com
	As of February 5, 2020

Founder Eli Lilly

Eli Lilly's business in 1885

Headquarters in Indianapolis

Germany headquarters in Bad Homburg

The Eli Lilly and Company counts with more than 33,000 employees worldwide, manufacturing facilities in 13 countries and a worldwide annual sales of over 22 billion US dollars (2019) to the big pharmaceutical companies in the world. It was founded in Indianapolis in 1876 by pharmacologist, officer and entrepreneur Eli Lilly .

The company's top-selling active ingredients are: Trulicity ( dulaglutide ), Humalog ( insulin lispro ), Alimta ( pemetrexed ), Forteo ( teriparatide ) and Taltz ( ixekizumab ).

history

In 1923 Lilly launched the first insulin preparation (Iletin) for diabetes mellitus, which had been deadly until then . In the 1930s, the company also manufactured phage therapeutics, until in 1943 it was the first company to start mass production of the antibiotic penicillin (replacing phage therapeutics) . In the 1950s, Eli Lilly was one of the companies involved in the production of the first polio vaccine developed by Jonas Salk . In 1982 Lilly introduced the world's first genetically engineered anti-diabetic drug . Eli Lilly later rose to become one of the leading pharmaceutical companies , not only in the USA , in particular with the antidepressant Prozac ( fluoxetine ) .

In 2008, after a bidding competition with Bristol-Myers Squibb , Lilly took over the American biotech company ImClone , the developer of a monoclonal antibody ( cetuximab ) for cancer therapy. In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced a global agreement to jointly develop and commercialize diabetes active ingredients. Boehringer Ingelheim's oral antidiabetic drugs - Linagliptin and BI 10773, as well as Lilly's two basal insulin analogues - LY2605541 and LY2963016 are currently in the middle and late stages of clinical development. On April 22, 2014, Lilly acquired Novartis' veterinary pharmaceuticals business for $ 5.4 billion .

In 2017, Eli Lilly and Company began planning the spin-off of its animal health division, Elanco Animal Health . Initially, almost 20% of the shares were listed on the stock exchange in 2018. Elanco has been completely independent since March 2019.

Lilly Germany

Eli Lilly was founded in Germany on May 12, 1960 as a branch, initially in Frankfurt am Main; For cost reasons, the headquarters were initially relocated to Giessen and later to Bad Homburg . Today Lilly is represented at the following locations (main areas of activity in brackets):

Bad Homburg vor der Höhe (since 1971, today Lilly Deutschland GmbH and Lilly Pharma Holding GmbH : company management, marketing and sales, IT, administration, veterinary drugs)
Norderfriedrichskoog (registered office of Lilly Pharma Produktion GmbH & Co. KG : production while avoiding trade tax )

The Giessen location was closed in 2014. ⊙ (from 1962, was the seat of Lilly Pharma Produktion und Distribution GmbH & Co.KG with production, delivery and distribution center for Europe: packaging of 40 million drug units / year and shipping to 90 countries) The Lilly company employed in Germany in 2010 more than 1,000 employees who achieved sales of 502 million euros in 2009 (2008: 1,051 employees and 483.3 million euros in sales). 50.612997 8.705335

criticism

The company has been criticized for suppressing studies of the side effects of its drugs in order not to jeopardize the approval of these drugs. Criticism of Lilly was expressed in connection with the approval of fluoxetine . John Virapen , former managing director of Eli Lilly and Company in Sweden, reports in his book "Side Effect Death" about the company's marketing strategies and corruption in the course of the launch of fluoxetine as an antidepressant.

In connection with the marketing of the antipsychotic drug Zyprexa (active ingredient: olanzapine ), Eli Lilly has paid a total of US $ 1.2 billion in extrajudicial compensation payments in around 28,500 cases since 2005 (as of February 2007). The background to this were side effects such as extreme weight gain and diabetes , which the manufacturer was aware of, but were kept secret or downplayed in public reports. In addition, the drug had been illegally marketed to patient groups for which it was not indicated. In December 2006, several hundred internal documents were released that document these practices in detail. First, the New York Times reported in several cover stories about the illegal marketing practices.